A 56-year-old patient with well-controlled type 2 diabetes and hypertension comes to the APRN for routine follow-up. His blood pressure is controlled with lisinopril 40 mg/day, but his albumin-to-creatinine ratio is 75 mg/g. The patient's records show that his albuminuria is getting progressively worse. The APRN wonders whether the combination of an angiotensin-converting enzyme (ACE) inhibitor and an ARB would slow the decline of renal function, and whether the combination would reduce the patient’s cardiovascular risk. What should the APRN implement in order to address the patient's albuminuria?

Choice A reason: Dual blockade with ACE inhibitors and ARBs has been studied but is not recommended due to increased risk of adverse effects such as hyperkalemia, hypotension, and acute kidney injury. It does not provide additional renal protection and may worsen outcomes. Choice B reason: Thiazide diuretics are useful for blood pressure control, especially in volume overload, but they do not specifically address albuminuria. They are not the preferred agents for reducing proteinuria. Choice C reason: Even though blood pressure is controlled, progressive albuminuria indicates ongoing renal damage. Doing nothing overlooks the need for targeted intervention to reduce proteinuria and preserve kidney function. Choice D reason: Calcium channel blockers, particularly non-dihydropyridine types like verapamil or diltiazem, have shown benefit in reducing proteinuria. They can be added to ACE inhibitors to enhance renal protection without the risks associated with dual renin-angiotensin system blockade.